Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Share-based Compensation: 2019-2025

Historic Share-based Compensation for Kymera Therapeutics (KYMR) over the last 6 years, with Sep 2025 value amounting to $15.8 million.

  • Kymera Therapeutics' Share-based Compensation rose 6.03% to $15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $59.2 million, marking a year-over-year increase of 13.70%. This contributed to the annual value of $55.0 million for FY2024, which is 27.58% up from last year.
  • Per Kymera Therapeutics' latest filing, its Share-based Compensation stood at $15.8 million for Q3 2025, which was up 2.51% from $15.4 million recorded in Q2 2025.
  • Kymera Therapeutics' Share-based Compensation's 5-year high stood at $15.8 million during Q3 2025, with a 5-year trough of $3.2 million in Q1 2021.
  • Its 3-year average for Share-based Compensation is $13.1 million, with a median of $13.8 million in 2024.
  • Data for Kymera Therapeutics' Share-based Compensation shows a peak YoY spiked of 762.35% (in 2021) over the last 5 years.
  • Kymera Therapeutics' Share-based Compensation (Quarterly) stood at $8.7 million in 2021, then climbed by 2.66% to $8.9 million in 2022, then rose by 22.33% to $10.9 million in 2023, then increased by 26.62% to $13.8 million in 2024, then rose by 6.03% to $15.8 million in 2025.
  • Its Share-based Compensation was $15.8 million in Q3 2025, compared to $15.4 million in Q2 2025 and $14.2 million in Q1 2025.